ASLAN PHARMACEUTICALS LIMITED

(ASLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aslan Pharmaceuticals Working With Iqvia Biotech on Clinical Trials

12/06/2021 | 08:14am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASLAN PHARMACEUTICALS LIMITED -1.43% 0.447 Delayed Quote.-60.09%
IQVIA HOLDINGS INC. 0.04% 201.83 Delayed Quote.-28.46%
All news about ASLAN PHARMACEUTICALS LIMITED
05/20ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Me..
GL
05/20ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Me..
GL
05/20ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal..
CI
05/19Asian ADRs Climb Higher in Thursday Trading
MT
05/18Asian ADRs Move Lower in Wednesday Trading
MT
05/18ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
GL
05/18ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
AQ
05/17Asian ADRs Move Up in Tuesday Trading
MT
05/13Asian ADRs Move Up in Friday Trading
MT
05/11Asian ADRs Move Higher in Wednesday Trading
MT
More news
Analyst Recommendations on ASLAN PHARMACEUTICALS LIMITED
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -1 611 M -54,2 M -54,2 M
Net Debt 2022 - - -
P/E ratio 2022 -0,55x
Yield 2022 -
Capitalization 927 M 31,2 M 31,2 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 27
Free-Float 41,2%
Chart ASLAN PHARMACEUTICALS LIMITED
Duration : Period :
ASLAN Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASLAN PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,45 $
Average target price 8,00 $
Spread / Average Target 1 690%
EPS Revisions
Managers and Directors
Carl Aslan Jason Morton Firth Chief Executive Officer & Director
Kiran Kumar Asarpota Chief Operating Officer & Head-Finance
Andrew James Howden Non-Executive Chairman
Alexandre Kaoukhov Chief Medical Officer
Robert E. Hoffman Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASLAN PHARMACEUTICALS LIMITED-60.09%31
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612